Background:
This clinical trial is studying whether the time of day when treatment is given can affect how well it works and what side effects patients experience. The treatment being studied is a standard combination of two immunotherapy drugs: nivolumab and ipilimumab, which are already used to treat advanced kidney cancer.
Both of these medicines help the body’s immune system fight cancer, but they work in slightly different ways.
Nivolumab helps the immune system “see” and recognize cancer cells by blocking a signal that cancer uses to hide.
Ipilimumab works by removing a natural “brake” on immune cells, allowing them to attack cancer more strongly. When used together, these drugs can improve the immune system’s ability to find and destroy cancer cells.
Researchers are interested in something called the circadian rhythm, which is the body’s natural 24-hour internal clock. This clock can affect how the immune system works at different times of the day. Because of this, the timing of treatment (morning vs. afternoon) may influence how well these drugs work and how likely side effects are.
The Trial:
This study is looking at whether the time of day you receive treatment can affect how well it works and what side effects you may have.
Participants will be randomly assigned to one of two groups:
- Receive your usual treatment in the morning (before 11:30 AM), or
- Receive your usual treatment in the afternoon (after 1:30 PM)
The trial is not “blind”, so both you and your doctor will know which therapy you are receiving.
Basic Eligibility:
- Are 18 years or older
- Have been diagnosed with advanced clear cell kidney cancer
- Are able to receive standard treatment with nivolumab and ipilimumab
Additional eligibility criteria will apply. Please speak to your doctor.
| Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
|---|---|---|---|
| Hospital / Cancer CentreBC Cancer Centre | Principal InvestigatorNot Given | LocationVancouver, BC | Trial StatusNot yet recruiting |
